Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shenzhen Chipscreen Raises $148 Million in Shanghai STAR IPO at $1.2 Billion Valuation

publication date: Aug 1, 2019

Shenzhen Chipscreen Biosciences priced its Shanghai STAR Board IPO to raise $148 million at a $1.2 billion valuation, the first China pharma to list on the new exchange. Demand for STAR IPOs continues to be off-the-chart strong: Chipscreen's IPO price reflects a PE ratio of 468, a record for the exchange so far. Chipscreen's block of stock reserved for retail investors was almost 3,000 times oversubscribed. After the first group of STAR IPOs began trading, they rose an average of 140%. Chipscreen is expected to be begin trading as soon as August 12. More details....

Stock Symbol: (SHA: 688321)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.